E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Embryo implantation in women undergoing IVF or ICSI with Day 3 or Day 5 fresh embryo transfer cycles, in the context of Assisted Reproductive Technology (ART). |
|
E.1.1.1 | Medical condition in easily understood language |
Embryo implantation in women undergoing IVF or ICSI with fresh embryo transfer cycles, in the context of Assisted Reproductive Technology (ART). |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Reproductive physiologi cal processes [G08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10073184 |
E.1.2 | Term | Embryo transfer |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to confirm the efficacy of a single oral 900 mg dose of nolasiban to increase the ongoing clinical pregnancy rate at 10 weeks post-embryo transfer (ET) day. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to assess the efficacy of a single oral 900 mg dose of nolasiban to increase the live birth rate |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. The Subject must provide written informed consent prior to initiation of any study related procedures, as shown by a signature on the informed consent form. 2. The Subject must be aged 18 years to 36 years inclusive at screening. 3. The Subject must be indicated for IVF/ICSI in the context of assisted reproductive technology (ART). 4. The Subject must have undergone not more than one unsuccesful (negative βhCG test) COH for IVF or ICSI (whether fresh and/or several frozen ET resulted from that COH). Any attempts before a prior clinical pregnancy (observed embryo with heart beat) do not count. 5. The Subject must in the current COH cycle for IVF/ICSI follow a GnRH antagonist protocol with or without pre-treatment with an oral contraceptive pill or estradiol. 6. The Subject must in the current COH cycle for IVF/ICSI receive a single injection of hCG for triggering final follicular maturation. 7. The Subject must in the current COH cycle for IVF/ICSI receive a luteal phase support with vaginal micronized progesterone at 600 mg per day (or local alternative if not available) beginning the morning after OPU. 8. The Subject must undergo oocyte retrieval for IVF/ICSI and subsequent fresh transfer on day 3 or day 5 post-OPU day. 9. The Subject must have at least one good quality embryo in the current COH cycle. 10. The Subject is scheduled for a single fresh embryo transfer in the current COH cycle. 11. The Subject must have at least 1 functional ovary. 12. The Subject must have a BMI ≥ 18 kg/m2 and ≤ 38 kg/m2. 13. The Subject must be able to communicate well with the investigator and research staff and to comply with the requirements of the study protocol. |
|
E.4 | Principal exclusion criteria |
1. The Subject undergoes a frozen-thawed embryo transfer in the current COH cycle. 2. The Subject’s partner required surgical testicular sperm extraction. 3. The Subject or partner has a known abnormal karyotype or the subject has known acquired or congenital thrombophilia disease. 4. The Subject has any condition, including findings in the medical history or in the pre-trial assessments, which in the opinion of the PI constitutes a risk or a contraindication for the participation of the subject in the trial or that could interfere with the trial objectives, conduct or evaluation. 5. The Subject has any clinically significant abnormality in the results of the screening safety laboratory tests, including AST, ALT, GGT, alkaline phosphatase or total bilirubin above twice upper limit of normal. In case of isolated GGT increase, a single re-test is allowed. 6. The Subject has a serum P4 level greater than 1.5 ng/mL on the day of hCG administration. 7. The Subject had more than 20 oocytes retrieved in the current COH cycle. 8. The Subject has any significant abnormality relevant to the ART procedure and outcome, in the results of the screening gynecological examination, which in the opinion of the PI could interfere with the trial objectives, conduct or evaluation (e.g. significant uterine anomaly, hydrosalpinx or fibroid(s) documented during screening ultrasound). 9. The Subject has a known severe endometriosis (stage III or IV) and/or adenomyosis. 10. The Subject is at significant risk of severe Ovarian Hyper Stimulation Syndrome (OHSS). 11. The Subject has any clinically significant abnormality on arterial blood pressure (BP) or heart rate (HR) at screening. 12. The Subject has known positive results from virology tests for hepatitis B surface antigen (HBsAg) (not due to vaccination), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) 1 or 2. However, subjects who have resolved hepatitis B infection may be enrolled in the study. 13. The Subject is prone to frequent, severe hypersensitivity to drugs. 14. The Subject has been administered with any experimental drug in the 12 weeks before dosing. 15. The Subject is likely to require treatment with drugs that are not permitted during the study from the day after OPU up to the the Week 2 visit (OPU day + 14 days) such as: • Drugs with utero-relaxant properties: Ca channel blockers, beta-sympathomimetic agents, nitroglycerine, magnesium sulfate (MgSO4), potassium channel openers, NSAIDs, drugs for functional GI disorders • Drugs with utero-tonic properties: Dopamine, progesterone antagonists, prostaglandin analogues • Triptans and ergotamines 16. The Subject has a history of, or known current (within twelve months) problems with alcohol or drug abuse. 17. The subject has a history of recurrent pregnancy loss defined as 3 or more consective pregnancy losses including biochemical pregnancies. Miscarriage prior to a live birth does not count. 18. The subject has a history of difficult transfers (e.g. tenaculum use or blood stained cathether). 19. The subject undergoes a D3 transfer after the randomization limit for D3 transfers has been reached or the subject undergoes a D5 transfer after the randomization limit for D5 transfers has been reached. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Intra-uterine pregnancy with fetal heart beat at 10 weeks post-ET day. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
As soon as the last subject has completed the last scheduled visit up to Week 10 visit and all data up to this visit have been entered into the clinical database, cleaned and locked, the results for the study will be analysed up to the Week 10 visit and described in a Clinical Study Report. |
|
E.5.2 | Secondary end point(s) |
Live birth after 24 weeks of gestation. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
after the data from the Pregnancy Outcome and Neonatal Health forms are available and the information from the ASQ-3 has been collected |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For administrative and safety reporting purposes the end of the study will be defined as the date of the final clinical database lock (including the pregnancy, neonatal and infant 6-month follow-up). This provides a single and conservative definition across all study sites. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |